Verastem Oncology CEO Stuglik retires; President Paterson appointed CEO effective Aug 1

Verastem, Inc.

CEO Brian Stuglik retires effective July 31, 2023; receives $421,850 cash bonus.
President Dan Paterson appointed President and CEO effective August 1, 2023; also joins Board.
Paterson has 30+ years experience, led acquisition of avutometinib; company moving toward FDA approval in LGSOC.
Stuglik remains on Board and chairs new Commercialization Committee.
Committee members Kapur and Tollefson; annual retainers $10k, chair $20k.

item 5.02 item 8.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Brian Stuglik

Chief Executive Officer

VSTM · Verastem, Inc.

Effective: 2023-07-31
Successor: Daniel Paterson
Filed: July 12, 2023, 7:59 PM ET

On July 7, 2023, Brian Stuglik notified Verastem, Inc. (the “Company)” of his decision to retire as Chief Executive Officer of the Company, effective July 31, 2023

Role change

Daniel Paterson

President and Chief Executive Officer

VSTM · Verastem, Inc.

Effective: 2023-07-31
Filed: July 12, 2023, 7:59 PM ET

Daniel Paterson, 62, the Company’s President and Chief Operating Officer, will be appointed to the position of President and Chief Executive Officer as of the Effective Date.

Appointed

Daniel Paterson

Class III director

VSTM · Verastem, Inc.

Effective: 2023-07-31
Filed: July 12, 2023, 7:59 PM ET

In connection with his appointment, Mr. Paterson will also be appointed to the Board, to serve as a Class III director.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 1.0

Brian Stuglik retired as Chief Executive Officer at Verastem, Inc..

Action: retired
Role: Chief Executive Officer

Exact text from the filing

On July 7, 2023, Brian Stuglik notified Verastem, Inc. (the “Company)” of his decision to retire as Chief Executive Officer of the Company, effective July 31, 2023

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 1.0

Daniel Paterson was appointed as President and Chief Executive Officer at Verastem, Inc..

Action: appointed
Role: President and Chief Executive Officer

Exact text from the filing

Daniel Paterson, 62, the Company’s President and Chief Operating Officer, will be appointed to the position of President and Chief Executive Officer as of the Effective Date.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 1.0

Daniel Paterson was appointed as Class III director at Verastem, Inc..

Action: appointed
Role: Class III director

Exact text from the filing

In connection with his appointment, Mr. Paterson will also be appointed to the Board, to serve as a Class III director.

View on SEC.gov

Verastem, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-23-080188

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.